Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos


ASCO GU 2023, urothelial carcinoma, bladder cancer, neoadjuvant chemotherapy (NAC), gemcitabine, cisplatin, plus nivolumab, muscle-invasive bladder cancer, pathologic complete responses (pCR), HCRN GU16-257 trial.

  • 123456 Profile photo of Madelyn

    Very interesting MIBC trial by Galsky et al. evaluating gemcitabine, cisplatin, nivolumab after TURBT, which was associated with clinical CR rate 43%. Standardized clinical response assessment with complete CR definition identified patients with favorable oncologic outcomes despite bladder preservation. Results support further studies of personalized strategies in the management plan of localized MIBC, utilizing risk stratification based on clinical response assessment. Optimization of clinical staging using several tools can be a key in that effort.